chemicals
Commented by Lars Winter on July 29th, 2026 | 07:20 CEST
New Buy Recommendations for Evonik, Fuchs, and Zefiro Methane: Analysts See Price Potential of Over 240%
Fresh Buy recommendations are fueling new price momentum for Zefiro Methane, Evonik, and Fuchs. The outlook for Zefiro is particularly spectacular. Following the turnaround in its operating performance, GBC believes the stock could multiply in value. But analysts are also forecasting double-digit price gains for the two German chemical stocks. When analysts raise their forecasts and recommend buying a stock, it is often worth taking a closer look. It becomes particularly interesting when these optimistic assessments are backed up by surprisingly strong financial results. That is exactly the case right now with Zefiro Methane, Evonik, and Fuchs. While the two German companies are already operating profitably and impressing with strong quarterly results, Zefiro is only at the beginning of a potential revaluation. The upside potential is correspondingly greater, though the risk is higher as well.
Read
Commented by Stefan Bode on July 23rd, 2026 | 07:45 CEST
Most Valuable Companies: Undervalued and Poised for a Turnaround? ASML, BASF, Desert Gold
Despite the wars in Ukraine and Iran, the current stock market environment remains bullish, and there are always companies emerging as promising candidates for the next investment. This report analyzes three promising stocks from three different sectors. First is a European technology giant that, thanks to its monopoly position, is aiming for a trillion-dollar valuation. Next is a heavily undervalued gold explorer that is on the verge of making the lucrative leap to becoming a producer. Finally, we examine a global leader in the chemical industry whose recent surges in operating profits could signal a genuine turnaround. Discover the potential of these stocks now.
Read
Commented by Carsten Mainitz on July 15th, 2026 | 08:15 CEST
The Future of Food: Major Opportunities for MustGrow and K+S! What is Next for Evotec After the Sell-Off?
Created and published on behalf of MustGrow Biologics Corp.
The global food supply is undergoing a profound transformation. A growing world population, climate change, and increasingly stringent environmental regulations are creating both challenges and opportunities for companies with the right solutions. Through its focus on biological crop protection and regenerative agriculture, MustGrow is targeting future markets worth billions. Analysts see significant upside potential for the stock. How should investors position themselves now?
Read
Commented by Nico Popp on July 7th, 2026 | 07:15 CEST
This Market Is Growing 17.1% Annually: Bayer and KWS SAAT Rethink Their Strategies – MustGrow Biologics Gains Momentum
Created and published on behalf of MustGrow Biologics Corp.
It is not only drought that is putting pressure on farmers. Regulators are increasingly banning chemical active ingredients that have been used for decades in an effort to protect soils and consumers. Already, 168 countries have significantly restricted or completely banned the use of approximately 568 chemical pesticides. At the same time, the European Union aims to have at least 25% of its agricultural land farmed organically by 2030. As many highly effective products are being phased out, farmers around the world are facing growing challenges. The question of how to maintain crop yields under these changing conditions has become a key concern for industry. This trend is fueling the biopesticides market, which, according to current industry forecasts by Fortune Business Insights, is expected to grow at a compound annual growth rate (CAGR) of 17.1%, reaching USD 40.61 billion by 2034.
Read
Commented by Matthias Schomber on June 29th, 2026 | 06:45 CEST
Soaring Stock Prices, a Billion-Dollar Ruling, and the Green Transition: The Big Return Showdown Between Lufthansa, Bayer, and A.H.T. Syngas
Sometimes, a single court ruling is enough to fundamentally alter the outlook for a listed company. Bayer demonstrated this vividly this week. Meanwhile, Lufthansa is climbing to new annual highs, supported by falling oil prices and a surprisingly stable credit rating. Then there is A.H.T. Syngas, a small but ambitious provider of biomass power plants that has either just emerged from a consolidation phase, or may be approaching the end of one. Three very different companies, three distinct stages of development—yet all three are worth a closer look at this moment. If you want to understand where opportunities may lie and where caution is warranted, read on.
Read
Commented by André Will-Laudien on June 16th, 2026 | 07:25 CEST
USA–Iran: The Strait of Hormuz is Opening Up! A Sector Buy Signal for Bayer, MustGrow, BASF and K+S!
Created and published on behalf of MustGrow Biologics Corp.
Some things are ultimately not surprising. The "agreement" between the USA–Israel and Iran resembles shadow boxing. One step forward, one step back—that is how the movements at the trading desk appear. The stock markets are reacting accordingly. At the start of the week, optimism about a near-term end to the hostilities is once again dominating. Oil prices are correcting most sharply, down nearly 5%, with Brent now quoted at only USD 82.50 per barrel. This is a positive signal for chemical- and transport-oriented industries in the food sector, with BASF and Bayer showing corresponding strength. Large volumes of goods must be transported globally, and shipping routes carry significant operational importance. As part of efforts to ensure long-term food security, more and more ideas are emerging that could mitigate the international energy crisis. MustGrow focuses on natural ingredients rather than chemicals, while K+S represents a typical example of the "old economy" in this sector. For investors, multiple opportunities for returns are available!
Read
Commented by Nico Popp on June 11th, 2026 | 07:00 CEST
Secure Supply Chains for BASF and Others: Antimony Shortage Threatens Production – Antimony Resources Follows Lynas Rare Earths' Lead
Created and published on behalf of Antimony Resources Corp.
Escalating trade wars, a global supply shortage, and historic price shocks – the market for critical industrial metals is undergoing a profound transformation. Following extensive export restrictions by the People's Republic of China and a complete export ban to the US at the end of 2024, antimony prices outside China skyrocketed to an all-time high of USD 59,750 per ton. The severe imbalance between Western demand and available supply outside China led to significant supply bottlenecks in 2025—Fastmarkets recorded the sharpest price rally in the history of the antimony market that year. Since authoritarian states control around 80% of global mine production, the Western high-tech and defence industries face a potentially existential supply risk for electronic components and industrial fire-retardant applications. We explain the situation and present a potential solution.
Read
Commented by André Will-Laudien on June 2nd, 2026 | 06:55 CEST
Stock Market Rotation Beyond AI: Opportunities in MustGrow, Bayer, and Novo Nordisk; Caution with K+S
Created and published on behalf of MustGrow Biologics Corp.
A shift in perspective remains the order of the day. Yesterday, the ECB met to discuss the current situation regarding inflation and interest rates. With an inflation rate of over 3% in Europe, there is likely no room for downward interest rate adjustments—quite the opposite! The 10-year yield on German government bonds has settled near the 3% mark over the past four weeks, while in the US, the 30-year yield is already above 5%. In the past, these were warning signs for a currently well-valued NASDAQ, as the so-called trailing P/E ratio has soared from 28 to 36. Growth companies, mostly financed through equity, thrive on tech euphoria, whereas capital-intensive industries, such as the life sciences sector, face a different situation. For example, Bayer and Novo Nordisk do not require market financing, as they hold large cash reserves. In the case of K+S, the ability to pass on prices to end customers could lead to rising cash flows, while the Canadian company MustGrow has only recently raised funds and is steadily continuing its rollout in the US. Mid-term investors should focus on sector rotation when tech momentum fades. The chances of a revival in neglected sectors look strong!
Read
Commented by Armin Schulz on May 28th, 2026 | 08:30 CEST
Bayer, MustGrow Biologics, K+S: The Secret Formula for Success Behind the Biological Fertilizer Revolution
Created and published on behalf of MustGrow Biologics Corp.
The global fertilizer industry is undergoing its most significant structural transformation in generations. A growing global population, technological breakthroughs in biological agricultural solutions, and policy shifts toward more sustainable agriculture are driving this growth sector. The need for more efficient nutrient use is giving rise to a dynamic market with fresh revenue potential. Companies that pursue the right strategies now are positioning themselves for the coming decade. Three players from different worlds embody this development in their own way: Bayer, MustGrow Biologics, and K+S.
Read
Commented by Fabian Lorenz on May 27th, 2026 | 07:50 CEST
SELL BASF and Hensoldt? BUY Recommendation for Power Metallic Mines
Caution is advised with Hensoldt. Analysts see a potential 30% downside for the stock. The company is trading at a premium to industry peers such as Rheinmetall and Renk, despite slower growth. While the partnerships with Helsing and Schwarz Digits are interesting, they are unlikely to contribute significantly to revenue in the foreseeable future. In contrast, analysts see 100% upside potential for Power Metallic Mines, specifically in the base-case scenario. The first resource estimate is scheduled for this summer. According to analyst estimates, the company could thus transition from a pure exploration valuation to a resource-based valuation phase sooner than previously expected. Analysts foresee difficult times ahead for BASF. The structural problems remain unresolved, and the stock is a "Sell". The chemical giant is attempting to counter these challenges through optimization measures and the increased use of AI technologies.
Read